What reimbursement for coronary revascularization with drug-eluting stents?
- 83 Downloads
We investigated the clinical and economic impact of sirolimus-eluting coronary stents (SES) at a nationwide level as to advice about the feasible reimbursement policy for the Italian Health Care System (SSN). A decision model compared bare metal stents (BMS) and SES in terms of costs and repeat coronary revascularizations incurred in 12 months following the first revascularization. The model was compiled for eight subgroups of patients. Rates of events were derived from randomized trials and an 1,809-patient survey. National charges were used to evaluate resources consumption. Compared with BMS, the number of averted revascularizations with SES is 0.16 per patient. SES also save €1,371 per patient. Total savings to SSN are proportional to the rate of SES adoption by Italian hospitals: assuming a complete replacement of BMS with SES, the model estimates that 7,095 revascularizations would be averted and more than €60 million saved by the SSN in 1 year. To stimulate SES adoption a SES-specific DRG might by introduced with a reimbursement value 23% higher than the current charge. SES is thus a cost-saving strategy in the perspective of the SSN that could therefore support the introduction of the new technology by reimbursing about 80% of its current incremental acquisition cost.
KeywordsCoronary stents Decision analysis Costs Coronary artery disease
The present study was carried out at Bocconi University and HEDM and was sponsored by Cordis Italia and Cordis Europe. The authors are grateful to the cardiologists that provided us with the survey data: Paolo Ravagnani and Antonio Bartorelli (Ospedale Cardiologico Monzino, Milan), Giulio Guagliumi (Spedali Riuniti, Bergamo), and Leonardo Bolognese (Ospedale Careggi, Florence).
Conflict of interest:
No information supplied
- 1.Abizaid AC (2002) Sirolimus for in-stent restenosis: final Sao Paulo and Rotterdam pooled results and lessons learned. http://www.tctmd.com
- 4.Banz K, Schwicker D (1997) Cost-effectiveness of Palmaz-Schatz feminine stenting for patients with coronary artery disease in Italy. Invasive Cardiol 9 [Suppl A]:29A–34AGoogle Scholar
- 6.Greenberg D, Bakhai A, Cohen DJ (2003) Do benefits of new technology outweigh the costs? The case of drug-eluting stents. J Drug Deliv 1:255–266Google Scholar
- 10.Morice M-C, Serruys P, Costantini C et al. on behalf of the RAVEL Trial Investigators (2003) Two-year follow-up of the RAVEL study: a Randomized study with the sirolimus-eluting Bx vELOCITY (tm) stent in the treatment of patients with de novo native coronary artery lesions. Presented at the American College of Cardiology Meeting, abstract 805–1Google Scholar
- 14.Cutlip DE, Chauhan MS, Baim DS et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 40:2082–2089Google Scholar